Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib plus cobimetinib with FDG/FLT PET monitoring in BRAF V600-mutant advanced melanoma
NL-OMON44689Phase 2Not yet recruiting
- Sponsor
- WIN-O
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib and cobimetinib in melanoma, sponsored by WIN-O. Primary endpoints: Progression-free survival, Correlation of PET tracer uptake changes with CT size changes and 2 more. Planned start Oct 2014; status: not yet recruiting.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON44689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44689.